Significance of macrophage inflammatory protein-1 alpha (MIP-1α) in multiple myeloma

References

• Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Reviews 2002; 13: 455–481
   PubMed Web of Science ®Google Scholar
• Lee S C, Brummet M E, Shahabuddin S, Woodworth T G, Georas S N, Leiferman K M, et al. Cutaneous injection of human subjects with macrophage inflammatory protein-1α induces significant recruitment of neutrophils and monocytes. Journal of Immunology 2000; 164: 3392–3401
   PubMed Web of Science ®Google Scholar
• Di Pietro L A, Burdick M, Low Q E, Kunkel S L, Strieter R M. MIP-1α as a critical macrophage chemoattractant in murine wound repair. Journal of Clinical Investigations 1998; 101: 1693–1698
   PubMed Web of Science ®Google Scholar
• Broxmeyer H E, Kim C H. Regulation of hematopoiesis in a sea of chemokine family members with a plethora of redundant activities. Experimental Hematology 1999; 27: 1113–1123
   PubMed Web of Science ®Google Scholar
• Watanabe T, Kukita T, Kukita A, Wada N, Toh K, Nagata K, et al. Direct stimulation of osteoclastogenesis by MIP-1alpha: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL. Journal of Endocrinology 2004; 180: 193–201
   PubMed Web of Science ®Google Scholar
• Kukita T, Nomiyama H, Ohmoto Y, Kukita A, Shuto T, Hotokebuchi T, et al. Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment. Laboratory Investigations 1997; 76: 399–406
   PubMed Web of Science ®Google Scholar
• Han J H, Choi S J, Kurihara N, Koide M, Oba Y, Roodman G D. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001; 97: 3349–3353
   PubMed Web of Science ®Google Scholar
• Choi S J, Cruz J C, Craig F, Chung H, Devlin R D, Roodman G D, Alsina M. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000; 96: 671–675
   PubMed Web of Science ®Google Scholar
• Uneda S, Hata H, Matsuno F, Harada N, Mitsuya Y, Kawano F, Mitsuya H. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. British Journal of Haematology 2003; 120: 53–55
   PubMed Web of Science ®Google Scholar
• Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1α) in monoclonal gammopathy of undetermined significance (MGUS). British Journal of Haematology 2004; 126: 686–689
   PubMed Web of Science ®Google Scholar
• Roodman G D, Choi S J. MIP-1 alpha and myeloma bone disease. Cancer Treatment Research 2004; 118: 83–100
   PubMedGoogle Scholar
• Blum S, Forsdyke R E, Forsdyke D R. Three human homologs of a murine gene encoding an inhibitor of stem cell proliferation. DNA Cell Biology 1990; 9: 589–602
   PubMed Web of Science ®Google Scholar
• Hirashima M, Ono T, Nakao M, Nishi H, Kimura A, Nomiyama H, et al. Nucleotide sequence of the third cytokine LD78 gene and mapping of all three LD78 gene loci to human chromosome 17. DNA Sequence 1992; 3: 203–212
   PubMedGoogle Scholar
• Menten P, Struyf S, Schutyser E, Wuyts A, De Clercq E, Schols D. The LD78 beta isoform of MIP-1 alpha is the most potent CCR5 agonist and HIV-1 inhibiting chemokine. Journal of Clinical Investigations 1999; 104: R1–R5
   Web of Science ®Google Scholar
• Min D J, Cho M L, Lee S H, Min S Y, Kim W U, Min J K, et al. Augmented production of chemokines by the interaction of type II collagen-reactive T cells with rheumatoid synovial fibroblasts. Arthritis & Rheumatism 2004; 50: 1146–1155
   PubMed Web of Science ®Google Scholar
• Kusugami K, Ando T, Imada A, Ina K, Ohsuga M, Shimizu T, et al. Mucosal macrophage inflammatory protein-1alpha activity in Helicobacter pylori infection. Journal of Gastroenterology & Hepatology 1999; 14: 20–26
   PubMed Web of Science ®Google Scholar
• Schuyler M, Gott K, French V. The role of MIP-1alpha inexperimental hypersensitivity pneumonitis. Lung 2004; 182: 135–149
   PubMed Web of Science ®Google Scholar
• Fuke S, Betsuyaku T, Nasuhara Y, Morikawa T, Katoh H, Nishimura M. Chemokines in bronchiolar epithelium in the development of chronic obstructive pulmonary disease. American Journal of Respiratory Cell Molecular Biology 2004; 31: 405–412
   PubMed Web of Science ®Google Scholar
• Zhao L, Moos M P, Grabner R, Pedrono F, Fan J, Kaiser B, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia- dependent aortic aneurysm. Natural Medicine 2004; 10: 966–973
   PubMed Web of Science ®Google Scholar
• Cook D N, Beck M A, Coffman T M, Kirby S L, Sheridan J F, Pragnell I B, Smithies O. Requirement of MIP-1 alpha for an inflammatory response to viral infection. Science 1995; 269: 1583–1585
   PubMed Web of Science ®Google Scholar
• Cocchi F, DeVico A L, Yarchoan R, Redfield R, Cleghorn F, Blattner W A, et al. Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8 + T cells are associated with asymptomatic HIV-1 infection. Proceedings of the National Academy of Sciences (USA) 2000; 97: 13812–13817
   PubMed Web of Science ®Google Scholar
• Owen-Lynch P J, Czaplewski L G, Hunter M G, Whetton A D. The growth inhibitory role and potential clinical value of macrophage inflammatory protein 1 alpha in myeloid leukemias. Leukemia & Lymphoma 1998; 30: 41–53
   PubMed Web of Science ®Google Scholar
• Kukita T, Nakao J, Hamada F, Kukita A, Inai T, Kurisu K, Nomiyama H. Recombinant LD78 protein, a member of the small cytokine family, enhances osteoclast differentiation in rat bone marrow culture system. Bone Minerals 1992; 19: 215–223
   PubMedGoogle Scholar
• Scheven B A, Milne J S, Hunter I, Robins S P. Macrophage-inflammatory protein-1alpha regulates preosteoclast differentiation in vitro. Biochemistry & Biophysics Research Communications 1999; 254: 773–778
   PubMed Web of Science ®Google Scholar
• Lean J M, Murphy C, Fuller K, Chambers T J. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. Journal of Cellular Biochemistry 2002; 87: 386–393
   PubMed Web of Science ®Google Scholar
• Hanyuda M, Kasama T, Isozaki T, Matsunawa M M, Yajima N, Miyaoka H, et al. Activated leucocytes express and secrete macrophage inflammatory protein-1alpha upon interaction with synovial fibroblasts of rheumatoid arthritis via a beta2-integrin/ICAM-1 mechanism. Rheumatology 2003; 42: 1390–1397
   PubMed Web of Science ®Google Scholar
• Toh K, Kukita T, Wu Z, Kukita A, Sandra F, Tang Q Y, et al. Possible involvement of MIP-1alpha in the recruitment of osteoclast progenitors to the distal tibia in rats with adjuvant-induced arthritis. Laboratory Investigations 2004; 84: 1092–1102
   PubMed Web of Science ®Google Scholar
• Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiology and management of bone disease in multiple myeloma. British Journal of Haematology 2003; 123: 758–769
   PubMed Web of Science ®Google Scholar
• Choi S J, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J, Roodman G D. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. Journal of Clinical Investigations 2001; 108: 1833–1841
   PubMed Web of Science ®Google Scholar
• Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 2002; 100: 2195–2202
   PubMed Web of Science ®Google Scholar
• Oyajobi B O, Franchin G, Williams P J, Pulkrabek D, Gupta A, Munoz S, et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003; 102: 311–319
   PubMed Web of Science ®Google Scholar
• Oyajobi B O, Mundy G R. Macrophage inflammatory protein-1a: osteolytic and tumour-promoting effects in myeloma bone disease. Haematologica 2005; 90(Suppl1)42–43
   Google Scholar
• Oba Y, Lee J W, Ehrlich L A, Chung H Y, Jelinek D F, Callander N S, et al. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Experimental Hematology 2005; 33: 272–278
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Abe M, Tanaka Y, Sekimoto E, Oshima T, Shibata H, et al. Macrophage inflammatory protein-1 may cause reciprocal regulation of osteoclast and dendritic cell differentiation from monocytes in myeloma. Haematologica 2005; 90(Suppl1)46
   Google Scholar
• Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. British Journal of Haematology 2004; 125: 38–41
   PubMed Web of Science ®Google Scholar
• Terpos E, Politou M, Szydlo R, Goldman J M, Apperley J F, Rahemtulla A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1α) correlate with the extent of bone disease and survival in patients with multiple myeloma. British Journal of Haematology 2003; 123: 106–109
   PubMed Web of Science ®Google Scholar
• Magrangeas F, Nasser V, Avet-Loiseau H, Loriod B, Decaux O, Granjeaud S, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 2003; 101: 4998–5006
   PubMed Web of Science ®Google Scholar
• Terpos E, Szydlo R, Apperley J F, Hatjiharissi E, Politou M, Meletis J, et al. Soluble receptor activator of nuclear factor-κB ligand (RANKL)/osteoprotegerin (OPG) ratio predicts survival in multiple myeloma. Proposal for a novel prognostic index. Blood 2003; 102: 1064–1069
   PubMed Web of Science ®Google Scholar
• Kraj M, Sokolowska U, Kruk B, Centkowski P. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients. Haematologica 2005; 90(Suppl1)193–194, (abstract)
   Google Scholar
• Michigami T, Shimizu N, Williams P J, Niewolna M, Dallas S L, Mundy G R, Yoneda T. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 2000; 96: 1953–1960
   PubMed Web of Science ®Google Scholar
• Kuehl W M, Bergsagel P L. Multiple myeloma: evolving genetic events and host interactions. Natural Reviews in Cancer 2002; 2: 175–187
   PubMed Web of Science ®Google Scholar
• Su S, Mukaida N, Wang J, Zhang Y, Takami A, Nakao S, Matsushima K. Inhibition of immature erythroid progenitor cell proliferation by macrophage inflammatory protein-1alpha by interacting mainly with a C-C chemokine receptor, CCR1. Blood 1997; 90: 605–611
   PubMed Web of Science ®Google Scholar
• Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara M Y. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003; 101: 3568–3573
   PubMed Web of Science ®Google Scholar
• Moller C, Stromberg T, Juremalm M, Nilsson K, Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003; 17: 203–210
   PubMed Web of Science ®Google Scholar